New Thread

Ctrl

Johnson & Johnson Stock Price: Quote, Forecast, Splits & News (JNJ)

Perplexity Finance

Company Profile

Johnson & Johnson Price & Performance (JNJ)

Stock Performance

Updated Apr 24, 8:00 PM UTC

Johnson & Johnson

$154.93USD

-$0.45 (-0.29%)

After Hours

+$0.46 (+0.3%)

Open

$155.80

Market Cap

$373.36B

Year High

$169.99

High

$155.90

P/E Ratio

17.2

Year Low

$140.68

Low

$153.44

Dividend Yield

3.20%

Volume

6.72M

Latest News

European Commission Grants Approval to TREMFYA for Ulcerative Colitis
Johnson & Johnson has secured European Commission approval for TREMFYA (guselkumab) to treat adults with moderately to severely active ulcerative colitis. This regulatory milestone strengthens the company’s presence in the inflammatory disease market, offering a new therapeutic option for patients and potentially expanding J&J’s revenue streams in Europe.12
Litigation Resumes as Johnson & Johnson’s Talc Bankruptcy Strategy Fails
Apr 21, 2025
After the collapse of Johnson & Johnson’s third bankruptcy attempt, federal litigation over talc-based products is moving forward. Over 90,000 lawsuits remain active, with the court now addressing key motions. The company’s decision not to appeal clears the way for potential bellwether trials and renewed settlement discussions.34
Tariff Costs Weigh on Johnson & Johnson’s MedTech Outlook
Apr 15, 2025
Johnson & Johnson anticipates $400 million in tariff-related charges this year, impacting its medtech segment. Despite these headwinds, the company reported a 2.5% increase in medtech sales for Q1 and slightly raised its 2025 sales guidance, signaling resilience amid ongoing global trade challenges.56

What's Happening

Peers

Earnings

Report Date

Apr 15, 2025

Reported Revenue

21.9B

Beat +1.55%

Avg 1d Change

1.91%

Report Period

Q1 2025

Reported EPS

2.8

Beat +7.36%

Implied Move 1d

2.29%

Transcript

6m 27s

A description of these risks, uncertainties, and other factors can be found in our SEC filings including our 2024 Form 10 ks, which is available at investor.jnj.com and on the SEC's website. Additionally, several of the products and compounds discussed today are being developed in collaboration with strategic partners or licensed from other companies. This slide acknowledges those relationships. Moving to today's agenda, Joaquin Duato, our Chairman and CEO, will open with a few comments on our performance and key catalysts for the company. John Reed, our Executive Vice President, Innovative Medicine R and D will highlight recent data from select assets. I will then review the first quarter sales and P and L results. Joe Walk, our CFO, will then close by sharing an overview of our cash position, capital allocation priorities, and guidance for 2025. Jennifer Taubert, Executive Vice President, Worldwide Chairman, Innovative Medicine and Tim Schmid, executive vice president, worldwide chairman, med tech, will be joining us for Q and A. To ensure we provide enough time to address your questions, we anticipate the webcast will last slightly over sixty minutes. With that, I will now turn the call over to Joaquin.

7m 52s

Thank you, Jess, and hello, everyone. In the first quarter, we delivered strong operational sales growth of 4.2% across our business. Our Q1 performance reinforces my confidence in our 2025 guidance and reflects the strength of Johnson and Johnson's uniquely diversified business. With year over year sales increases in both our innovative medicine and med tech sectors. No other healthcare company has delivered growth through the first year of losing exclusivity for a multibillion dollar product. In our case, [indiscernible] [indiscernible] what we are doing. Our resiliency is a testament to what makes us unique. We are not just a pharmaceutical company or a med tech company. We are a health care company. Innovating across the full spectrum of disease. Our consistent strong performance is a testament to our capabilities across commercial, R and D, and supply chain. It is also a reflection of our strength in execution which you can see in our quarterly results. We have described 2025 as a catalyst year. It is a year that will set us up for accelerated growth through the second half of the decade and beyond. In Q1, the power of our portfolio and pipeline was on full display. In Innovative Medicine, we delivered 4.2% operational sales growth despite an approximate eight ten basis points headwind from Stellara, 11 key brands growing double digits.

9m 45s

With our third consecutive quarter of sales above $3,000,000,000 DARZALEX continues to set the standard in multiple myeloma with another quarter of over 20% growth. In fact, just last week, we expanded our DARZALEX indication in Europe with the approval of a DARZALEX based quadruplet regimen for patients with newly diagnosed maternal myeloma regardless of transplant eligibility. It is further proof of the impact of this medicine which together with Carvik Talve and TegVaile is changing the conversation from treating to progression to treating to cure. Other significant oncology portfolio advancements in Q1 included Phase III data presented at ELCC last month showing Ribrovant plus Las Cruze extended overall survival by more than one year versus the current standard of care, in first line EGFR mutated lung cancer. And last week, the European Commission approved subcutaneous riblimid in combination with Las Cruze for the treatment of EGFR mutated non small cell lung cancer. This was an important milestone for patients as such cutaneous Ribrevant reduces administration time from hours to minutes. Our aspiration is for Ribrovant plus Cruces to become the new standard of care for these patients and you can see our progress in Q1. In immunology, we're seeing the impact of Tremfya's entry into inflammatory bowel disease.

11m 33s

With our launch in ulcerative colitis helping accelerate operational sales growth to 20%. And with our recent FDA approval in Crohn's disease, I'm more confident than ever that this blockbuster drug will become the gold standard for IBD patients and a $10,000,000,000 plus product. Turning to MedTech, in Q1, we delivered 4.1% operational sales growth with strong performance in our recently acquired cardiovascular businesses, Abiomed and Shockwave as well as in surgical vision and wound closure. In addition to their contribution to MedTech growth, Abiomed and Shockwave continued to meet deal model expectations and both announced important portfolio milestones this quarter. These included updates to the American College of Cardiology and American Heart Association guidelines for our Impella heart pump. Which based on evidence from the DANGER shock trial was upgraded from class two b to class two a. And in shock wave, the team launched the first of its kind, Javelin peripheral IVL catheter for the treatment of difficult to cross lesions in peripheral artery disease. In electrophysiology, we resumed US body pulse cases and to date, we have completed more than five thousand five hundred cases globally. Turning to surgery, we recently announced we have started OTAVA clinical trials a procedure that supports submission for U. S. FDA de novo in general surgery with an indication for multiple upper abdomen procedures.

13m 23s

This is an important milestone as we continue to strengthen our presence in robotic surgery. Beyond our existing portfolio and pipeline, we also ified our leadership as an innovation powerhouse with two major announcements. In March, we announced our commitment to invest more than $55,000,000,000 in The US over the next four years in manufacturing, R and D and technology. This represents a 25% increase in investment compared to the previous four years. It builds upon the company's already elevated commitment to The U. S. Economy while expanding our capacity to manufacture next generation medicine and devices for patients in America and around the world. The investment includes four planned new manufacturing facilities, the first of which broke ground last month in North Carolina. And at the April, we announced the completion of our acquisition of intracellular therapies which extends Johnson and Johnson's industry leading portfolio in central nervous system disorders. With the addition of CAPLYTA, we have expanded our lineup of therapies with least $5,000,000,000 plus potential in peak year sales. Further solidifying sales growth above analyst expectations now through the rest of the decade.

14m 56s

Turning to the TALK bankruptcy ruling. As we shared a few weeks ago, we will return to the third system where we expect continual success in litigating these meritless claims. In terms of next steps, we will immediately pursue our motion spending in the multi district litigation to exclude plaintiffs' experts known as the Daubert challenge. And finally, as announced this morning, we increased our dividend for the sixty third consecutive year which we know important to our shareholders. We had a strong start to 2025, and I'm looking forward to sharing many more successes throughout the year. Recognizing that there have been many important milestones and data readouts in the quarter I will now pass the call to John Reed for an innovative medicine r and d update.

15m 53s

Thank you, Joaquin.

15m 55s

I'm excited to share a few highlights from our industry leading innovative medicine pipeline that occurred throughout the quarter. With the successful acquisition of Intracellular, I want to focus on CAPLYTA, a remarkable medicine with balanced pharmacology that delivers robust efficacy combined with a favorable tolerability profile for neuropsychiatric disorders. CAPLYTA is already approved for the treatment [indiscernible] And is the only medicine approved for the treatment of depression in both bipolar one and two. As either monotherapy or adjunctive therapy. On this slide, we're sharing data for major depressive disorder showing very impressive and consistent improvements in the standard depression scoring metric, MADRS. In both phase three studies that served as the basis submission of the supplemental new drug application to the FDA. We anticipate approval of CAPLYTA later this year as an adjunctive treatment for major depressive disorder, representing the largest of the indications for novel antidepressant drugs today. Turning to oncology. We are so excited about our recent overall survival data for Ribrovant plus last clues in first line non small cell lung cancer harboring EGF receptor gene mutations. Non small cell lung cancer is the most prevalent type of lung cancer, making up about eighty five percent of lung cancer diagnoses.

17m 35s

Sadly, less than twenty percent of people diagnosed with this form of the disease are alive after five years, and only a fraction live long enough to try a second treatment. That's why it is so important to use the best treatment first. In a head to head study against today's standard of care, our Riborvant plus Lascluse regimen improved overall survival by more than a year. With the Kaplan Meier survival curves continuing to separate at thirty seven point eight months median follow-up. With Riborband's triple mechanism of action, we're looking to reset the standard five year survival expectations in a never before seen way. In simplest terms, we're giving patients more hope. That they may live to celebrate another birthday anniversary, or other important family event. A truly practice changing achievement. Now on to immunology. I draw your attention to the recent FDA approval of Tremfya in Crohn's disease, our fourth indication for Tremfya. Tremfya is currently the only I l twenty three inhibitor with the flexibility of subcutaneous administration for both induction and maintenance dosing for the treatment of Crohn's disease. Means patients can start their treatment by self administering with results as rapid and robust as receiving the IV in a clinic or doctor's office.

19m 14s

Additionally, in a recent head to head study, in adult patients with moderately to severely active Crohn's disease, Tremfya demonstrated superiority versus Stelara in all pooled endoscopic endpoints. As the only dual acting IL-twenty three inhibitor, Tremfya neutralizes IL-twenty three while also binding to c d 64, an immune cells that produce I o 23 thus localizing Trimphia right at the source of inflammation. Tremfya continues to offer an exceptional solution for patients struggling with inflammatory bowel disease. Lastly, highlighting some of our latest data for our investigational oral I l twenty three pathway inhibitor icotrokinra we are aiming to redefine the standard of care for people living with plaque psoriasis. [indiscernible] is the first and only targeted oral peptide that selectively blocks the I l 23 receptor. In two placebo controlled phase three studies, icotrokinra demonstrated impressive complete skin clearance and a favorable safety profile in a once daily pill.

20m 37s

Our phase three data demonstrated that nearly half of adult patients and three quarters of adolescents with moderate to severe plaque psoriasis treated with icotrigenra achieve completely clear skin by week twenty four. We also reported that icotrokinra achieved the prespecified endpoints in additional phase three psoriasis studies. Comparing our molecule head to head with the most commonly prescribed TYK2 inhibitor, Those data will be shared at an upcoming medical congress.

21m 12s

Looking forward, we are initiating the first ever head to head study seeking to demonstrate the superiority of a pill icotrokinra, compared to an injectable biologic, Stellara, in moderate to severe plaque psoriasis. Representing an important step forward in psoriasis research. As a reminder, we intend to file a Cotrokinra for approval later this year. Finally, beyond psoriasis, we recently announced positive top line results from Anthem UC, our Phase IIb study of icotrokinra in adults with moderate to severe ulcerative colitis. That study showed that icotrochinra achieved impressive clinical remission rates combined with a favorable safety profile again, dosed as a once daily pill. With all this progress, you can understand why we continue to be about the potential of icotrokinra to transform the treatment paradigm for patients battling with autoimmune diseases.

22m 22s

Overall, across all our therapeutic areas, we are absolutely thrilled with the progress that our pipeline has made in the first quarter of this year. And we are eager to report on other significant milestones scheduled for the remainder of 2025. And now I will turn the call over to Jess.

22m 40s

Thank you, John. Moving to our financial results. Unless otherwise stated, the percentages quoted represent operational results. And therefore exclude the impact of currency translation. Starting with Q1 twenty twenty five sales results. Worldwide sales were $21,900,000,000 for the quarter. Sales increased 4.2% to despite an approximate four seventy basis point headwind from Stellara. Growth in The U. S. Was 5.9%, and 2.1% outside of The U. S. Worldwide growth was positively impacted by 90 basis points due to acquisition and divestitures. Turning now to earnings. For the quarter, net earnings were $11,000,000,000 and diluted earnings per share was $4.54 versus diluted earnings per share of 1 point and 34¢ a year ago. Primarily driven by the reversal of $7,000,000,000 related to the talc settlement proposal. Excluding after tax intangible asset amortization expense, and special items for both periods, adjusted net earnings for the quarter were $6,700,000,000 and adjusted diluted earnings per share was $2.77. Representing increases of 1.92.2%, respectively, compared to the first quarter of twenty twenty four. We are proud to deliver bottom line growth despite the loss of exclusivity of Solara and the impact of Part D redesign.

24m 18s

I will now comment on business sales performance in the quarter. Beginning with Innovative Medicine, Worldwide sales of $13,900,000,000 increased 4.2%, despite an approximate eight ten basis point headwind from Stellara. Growth in The U. S. Was 6.3%, and 1.5% outside of The U. S. Starting with oncology, DARZALEX growth was 22.5%, primarily driven by continued share gains of three points across all lines of therapy and approximately five points in the frontline setting as well as market growth. PERVICTI achieved sales of $369,000,000 and growth of over 100%. Driven by share gains and capacity expansion. This reflects sequential growth of 10.5% as we continue to expand outside of The U. S. TechVeil and Talve growth was 1550.2%, respectively. Reflecting strong launches in the relapsedrefractory setting. Patient demand remained strong despite continued adoption of longer dosing intervals. ERLEADA continued to deliver strong growth of 14.6% despite the impact of Part D redesign, primarily driven by share gains and market growth. Riborvant plus Las Cruze continued its strong launch launch trajectory with sales of a hundred and $41,000,000 and growth over 100%. Within immunology, Tremfya delivered growth of 20.1% despite the impact of Part D redesign driven by share gains and market growth across all indications, including our newly launched indication in ulcerative colitis.

26m 8s

ZOLARA declined 32.3% driven by the impact of biosimilar competition and Part D redesign. As a reminder, REMICADE and SYMPANY distribution rights in Europe were returned in Q4. This positively impacted results in the quarter and is anticipated to continue for the remainder of the year. REMICADE sales also include a onetime patient mix benefit in The U. S. In neuroscience, growth of 42.9% was driven by increased physician and patient demand. Finally, other assets that were impacted by Part D redesign include Invega long acting injectables, which declined 13.5%. Pulmonary hypertension, which declined 1.2% and was partially offset by market growth and share gains. And Xarelto, which increased by 33%, and also included a onetime patient mix benefit. I'll now turn your attention to med tech. Worldwide sales of $8,000,000,000 increased 4.1% with growth of 5.1% in The US and 3% outside of The US.

27m 20s

Acquisitions and divestitures had a net positive impact of two eighty basis points on worldwide growth, four twenty basis points in The U. S. And 120 points outside of The U. S. Underlying MedTech performance was driven by commercial execution and strength of new products. Partially offset by several onetime events disproportionately impacting orthopedics. In addition to continued competitive PFA pressures in electrophysiology and headwinds in China. Results were negatively impacted by approximately two ten basis points worldwide. Two forty in The U. S, 180 outside of The US. Due to these onetime events. In cardiovascular, electrophysiology growth was roughly flat versus prior year driven by lapping of prior year inventory dynamics in Asia. Impacting worldwide results by roughly three ten basis points, and competitive PSA ablation catheter pressure. This was mostly offset by global procedure growth, new product uptake, and commercial execution. Abiomed delivered growth of 14% driven by strong growth in all regions and continued adoption of Impella 5.5 and Impella CP technology. Cardiovascular results also included $258,000,000 associated with the acquisition of Shockwave, As a reminder, we will lap the acquisition benefit at the May. Envision, contact lenses and other grew 2.7% driven by continued strategic price actions and strong performance in the AccuVue Oasis one day family of products.

29m 8s

Surgical vision growth of 6.2% was driven by our recent innovations, Technis Odyssey, PureC, and iHands. As well as commercial execution, partially offset by competitive pressures in The US. Surgery grew 1.1% with divestitures negatively results by approximately 180 basis points. Performance was driven primarily by commercial execution and the continued strength and adoption of new products across wound closure and biosurgery. Growth was partially offset by competitive pressures in energy and endocutters, as well as the negative impact of China VBP. Given the disproportionate impact of the onetime events to orthopedics, I'd like to draw your attention to this additional slide. Orthopedics declined 3.1% primarily driven by the lapping of a onetime revenue recognition timing change related to certain products across all platforms in The US. Fewer selling days and revenue disruption from the previously announced orthopedics transformation. These one time events negatively impacted worldwide orthopedics growth by approximately four eighty basis points. Six fifty basis points in The U. S. And two ten basis points outside of The U. S. This was partially offset by success of new product launches and commercial execution. Now turning to our consolidated statement of earnings for the first quarter of twenty twenty five.

30m 40s

I'd like to highlight a few noteworthy items that have changed compared to the same quarter of last year. Cost of products sold deleveraged by three twenty basis points driven by unfavorable transactional currency and product mix.

30m 54s

Primarily due to the decline of Stellara in Innovative Medicine. As well as the fair value step up in amortization associated with the Shockwave acquisition in MedTech. Selling, marketing and administrative expenses improved 130 basis points driven by operating spend management and phasing of investments, primarily in Innovative Medicine. Research and development expenses leveraged by 190 basis points primarily driven by portfolio progression towards commercialization and phasing of investments in innovative medicine. Partially offset by investments associated with the recent acquisitions of Shockwave and VWave in medtech. Interest income and expense with a net income of $128,000,000 as compared to $209,000,000 in the first quarter of twenty twenty four. Primarily driven by higher interest rates paid on higher average debt balances. Other income and expense was a net income of $7,300,000,000 compared to an expense of $2,400,000,000 in the prior year. Driven by the $7,000,000,000 talc reserve reversal in the first quarter of twenty twenty five and the $2,700,000,000 calc settlement proposal recorded during the first quarter of twenty twenty four. Regarding taxes in the quarter, our effective tax rate was 19.3% versus 12.4% in the same period last year. Primarily driven by the tax effect of the reversal of the talc settlement accrual.

32m 30s

Excluding special items, the effective tax rate was 16.3% versus 16.5% in the same period last year. I encourage you to review our upcoming first quarter ten Q filing for additional details on specific tax related matters. Lastly, I'll direct your attention to the box section of the slide where we have also provided the company's income before tax, net earnings, and earnings per share adjusted to exclude the impact of intangible amortization expense and special items. Now let's look at adjusted income before tax by segment for the quarter. New this quarter and to continue our efforts of increased financial transparency, you will find GAAP to non GAAP reconciliations by segment in the supplemental schedules of our press release. Innovative medicine margin declined from 42.9% to 42.5%, primarily driven by unfavorable transaction currency and product mix, and cost of products sold and Part D redesign. Partially offset by operating leverage. MedTech margin declined from 26.4% to 25.9%, primarily driven by r and d and selling, marketing and administrative investments associated with the recent acquisition of Shockwave and VWave. As a result, adjusted income before tax for the enterprise as a percentage of sales decreased from 36.8% to 36.6%. This concludes the sales and earnings portion of the call.

34m 7s

And I will now turn the call over to Joe.

34m 10s

Hello, everyone, and thank you for joining us today. Thanks, Jessica, not just for the transition now, also for how well you have led the investor relations function in the past few years. The investment community will miss you, but we look forward to seeing you in the lead finance role for Innovative Medicine. Our first quarter results demonstrate the strength and reliability of Johnson and Johnson's diversified business model. Innovative medicine achieved robust growth in the face of Stellara biosimilar entrants, we advanced our pipeline, attaining significant clinical and regulatory milestones. In med tech, as indicated in January, we anticipate a pockets of challenge early on and are planning for higher second half growth in those areas of our business. The team is focused on commercial execution and accelerating the recently launched products to deliver medtech's commitments that are included in the company's full year guidance. The recent acquisitions of Abiomed and Shockwave continue to expand our presence in higher growth markets. In addition, we continue to take steps to improve med tech's future margin profile. Implementing a restructuring program designed to simplify and focus the operations of our surgery business, similar to what we launched in orthopedics in 2023.

35m 22s

Focusing on portfolio renewal, we plan to exit certain non strategic product lines globally and optimize select sites across the network. We anticipate some modest short term revenue disruption in surgery of approximately $250,000,000 in total over the next two years, but these actions will improve our ability to accelerate growth and enhance profitability. The program is expected to be completed in 2027 with cost estimated at approximately $900,000,000. Let's now turn to cash and capital allocation. We are pleased with free cash flow generation in the quarter, of approximately $3,400,000,000. We ended the first quarter with $38,800,000,000 of cash and marketable securities, and $52,300,000,000 of debt for a net debt position of $13,500,000,000. It is important to note that cash and net debt were favorably impacted by $14,000,000,000 of cash held in of the Intracellular acquisition, which closed on April 2. Taking this into consideration, net debt would have been a $27,500,000,000. Investment and innovation remains the highest priority in our capital deployment. And during the first quarter, we invested more than $3,000,000,000 in research and development, approximately 15% of sales. We also remain committed to returning capital directly to shareholders. We recognize the value investors place on our dividend, and we were pleased to announce today that our board of directors authorized a 4.8% increase marking our sixty third consecutive year of dividend increases.

37m

The Intercellular Therapies acquisition bolsters our neuroscience portfolio and we maintain a disciplined approach to inorganic growth. Focusing on acquisitions and partnerships that align strategically and offer value creation. As noted in our talc investor call, and following up on some of Joaquin's earlier comments, we reversed $7,000,000,000 of the reserve previously held for the bankruptcy plan. This litigation has not, we foresee will not impact our ability to execute upon our capital allocation priorities to appropriately manage our business. Let's now discuss our full year guidance for 2025. We are increasing our operational sales guidance for the full year by $700,000,000 to reflect the addition of CAPLYTA following the completion of the Intercellular acquisition.

37m 50s

Therefore, we now expect operational sales growth for the full year to be in the range of 3.3% to 4.3% with a midpoint of $92,000,000,000 or 3.8%. Excluding the impact from acquisitions and divestitures, we are maintaining our adjusted operational sales growth to the range of 2% to 3% compared to 2024. As you know, we don't speculate on future currency movements, And last quarter, we utilized the euro spot rate relative to the US dollar of one point zero four. Last week, the euro spot rate relative to the US dollar was 1.11. We estimate an incremental positive foreign currency impact of $1,100,000,000 versus previous guidance, resulting in a full year headwind of $600,000,000. As such, we now expect reported sales growth between 2.6% to 3.6% with a midpoint of $91,400,000,000 or 3.1%. Turning to other notable items on the p and l, We are maintaining our guide of operating margin improvement by 300 points versus 2024. This improvement takes into consideration the dilution from the intracellular transaction as well as what we know today about the impact of tariffs on our business. We now project net interest between $100,000,000 and $200,000,000 primarily driven by financing costs associated with the Intracellular acquisition.

39m 24s

Other income is anticipated to be in the range of $1,000,000,000 to $1,200,000,000, a slight increase versus previous guidance. Despite 25¢ deletion from the intracellular acquisition and including the impact of tariffs based on what is in place today, we are pleased to be able to maintain our adjusted reported earnings per share guidance of 6.2% at the midpoint for a range of 10.5 to $10.70 partially by the reduced FX impact. I'll now provide some qualitative considerations on phasing for your models. We continue to expect both innovative medicine and med tech operational sales growth to be higher in the second half of the year versus the first half. Regarding Innovative Medicine, we maintain the assumption that the impact of Stellara biosimilar competition accelerate throughout the year similar to Humira's erosion curve which is still our proxy with the additive impact of Part d redesign. The impact of Part d redesign on affected products as a percent of sales will be consistently applied throughout the year. Aligned with how we traditionally account for similar discount and rebate programs. Naturally, we expect a greater benefit from our newly launched products as the year progresses. Regarding med tech, we expect normalized procedure volume and seasonality.

40m 45s

And, of course, we anniversary the shockwave acquisition at the May. We anticipate our newly launched products to build throughout the year with the relaunch of VariPulse in The US, the introductions of dual energy STSF, in The EU, [indiscernible] Gullis Spine, and Technis Odyssey. Lastly, this slide highlights the onetime prior year p and l items that should be taken into quarterly consideration for your models. Beyond our financial commitments and what Joaquin and John mentioned, we are excited for the pipeline progress plan for the remainder of 2025. In innovative medicine, this includes expected approvals in nipocalimab for generalized myasthenia gravis, subcutaneous ribavant for non small cell lung cancer in The US, Tremfya subcutaneous induction for ulcerative colitis, and CAPLYTA for adjunctive major depressive disorder. We continue our rolling submission of TAR 200 in non muscle invasive bladder cancer and anticipate filing a icotrochendra in psoriasis. And plan data readouts for Ribrovant head and neck cancer I coach Rikindra in ulcerative colitis as well as head to head data versus a tick to in psoriasis. In med tech, we continue to make progress with clinical trials for our OTOVA robotic surgical system and across our cardiovascular portfolio, including heart recovery with Impella ECP submission, and circulatory restoration with Javelin and Shockwave e eight launches.

42m 22s

This progress will bode well for financial performance for the balance of this decade. In fact, building on John's earlier discussion on our innovative medicine pipeline, and what I just outlined, I'd like to revisit and update a slide that we shared at our enterprise business review in late twenty twenty three. In that slide, you may recall we highlighted key assets in our portfolio that we expected to drive long term growth and projected higher revenue than street estimates. We've been pleased to see some estimates have been raised since the 2023 enterprise business review, And now I'd like to walk you through some of our current thinking on our pipeline potential. To show where we see even more upside. Based on current 2027 street estimates, our projections are at least two higher for Riborvant plus Last Clues and at least 50% higher for SPRAVATO. One asset that we didn't highlight in this look back in 2023 was Tremfya. However, given recent regulatory approvals for inflammatory bowel disease, we now see sales for Trimfya at least 25% higher than current street estimates. When looking ahead to 2028, we anticipate sales for our intravascular drug releasing system, previously referred to as TARS, to be at least three times higher than current street estimates, And new to the chart, icotrokinje, our targeted oral peptide, to be at least two times higher.

43m 48s

To be balanced, analyst estimates are still a bit more optimistic than our own estimates on nipocalimab in 2027. However, we do anticipate closing that gap. After launch. We have even stronger conviction today in our growth opportunities than at the enterprise business review as we've reached new milestones with each of these medicines. And importantly, we expect all these assets to achieve peak year sales beyond 2028 with further potential upside to street estimates in the outer years. Even after considering risk adjustments for unapproved products, that you may apply hopefully, you'll also conclude there is additional value to your outlooks.

44m 28s

In summary, it was a solid start to the year. Johnson and Johnson's diversified business model uniquely positions us to tackle the headwinds in 2025, deliver on our financial commitments, and advance our pipeline to create long term sustainable value for shareholders. Thank you. And with that, we are happy to take your questions. Kevin, will you please provide instructions for those seeking to participate in the q and a?

44m 52s

Certainly. We'll now be conducting a question and answer session. You'd like to withdraw your question, press star then 2. We ask you please limit yourselves to one question only. Our first question today is coming from Larry Biegelsen Wells Fargo. Your line is now live. Good morning. For taking the question, and congrats on a nice quarter. Joe, you talked about $400,000,000 in tariffs in the 2025 guidance or about 14¢ by our math. What is that on an annualized basis, and how are you thinking about being able to mitigate that over time? Can you can you pass along, you know, pass it along to customers, or or can you offset it by moving, production? Thanks for taking the question.

45m 40s

Yeah. Thanks, Larry. Good to hear from you. So what's included in the $400,000,000? And again, that is primarily med tech tariffs at this point. It's based on the programs that have been announced and the timing that correlates with those programs. So that would be inclusive of Mexico and Canadian import tariffs that are not excluded out of USMCA. It'll Include To A Very Small Degree Some Of The Steel And Aluminum Tariffs That Impact Some Of Our Products. It Includes The China tariffs, as well as the China retaliatory tariff. And that is probably the most substantial, out of all the tariffs in terms of that $400,000,000. And and so just to to maybe clarify for everybody, that that is products of US origin. Being shipped into China, and that's probably the most penalizing factor. That $400,000,000, I don't wanna be cavalier about that. It's obviously the the program has been phased in as a partial year. And then you have mostly this being captured as cost of goods. So it's going to sit on the balance sheet in inventory and be relieved to the p and l in future periods. So that's how that's how we're thinking of it.

46m 54s

In terms of mitigation strategies, I think you know, across our entire business, we're very limited in terms of price leverage. Whether it be on the med tech side, there's a contraction agreements already in place and certainly very much precluded on the pharmaceutical side. On current products that exist in terms of taking price increase And I know Joaquin has a few thoughts tariffs and maybe other mitigation factors and the supply nature of health care.

47m 22s

Thank you, Joe, and thank you, Larry, for the question.

47m 26s

Thinking about tariffs, and thinking specifically about pharmaceutical tariffs, there's a reason, Larry, why pharmaceutical tariffs are zero. It's because tariffs can create disruptions in the supply chain leading to shortages. If what you want is to build, manufacturing capacity in The U. S, both in medtech and in pharmaceuticals, The most effective answer is not tariffs, but tax policy. As a matter of fact, since, president Trump 02/2017 tax reform. The investment in manufacturing both in medtech and in pharmaceuticals has significantly increased. And when you think about our recent announcement of investing $55,000,000,000 over the next four years at the completion of this investment plan essentially all our advanced medicines that are used in The U. S. Will be manufactured in The U. S. So tax policy is a very effective tool to be able to build manufacturing here in The U. S. Both for medtech and pharmaceuticals.

48m 40s

Larry, I just wanna follow-up too. You did ask about a full year impact. And I I will say I purposely, ignored the only because it would be way too speculative at this point. As we know, these tariffs are very fluid, and the responsible action for us now is to quantify what we see the impact in 2026 and then see what happens with respect to, does it, lend itself to negotiations with other countries and what actually in place as we get into the the later part of 2025?

49m 10s

Thank you. Next question today is coming from Chris Schott from JPMorgan Chase and Company. Your line is now live. Great. Thanks so much. Just had a question on gross margins in the quarter. It seems like these came in well below recent trends. I'm just trying to get a better understand understanding of the drivers there.

49m 27s

And just the outlook going forward as we consider mix, tariffs, etcetera, on on the gross margin line? Thank you.

49m 33s

Hey, Chris. This is Joe. Thanks for the question. So I I I say it's a there's a two part answer to this one. So specifically, in the quarter, when looking at first quarter of twenty twenty four, we obviously had the impact of, Stellara, was a much higher gross margin product than our average product in our portfolio. You had part d, which is exclusively price, which is eroding margin. And then you had some, I would say, transactional currency headwinds. One, a favorable impact last year or in 2023. Funneling into 2024, and then some unfavorability from last year's, currency action. I would expect moving forward, based on some of the plans that we have, you could expect that that 300 basis points to probably improve by a third to 50%, and that would be inclusive of the tariff that I just mentioned in Larry's question. The other thing I would say is, I know you you guys do a great job, but I think analysts were maybe a little bit optimistic with respect to their outlook for gross profit, given that we had Stellara and Part d certainly communicated in the past. I believe the consensus was taking gross margins up.

50m 47s

Year over year. And that one, was probably a little bit of a miss, so we probably could 've done a better job explaining it.

50m 57s

Thank you. Next question is coming from Asad Hayder from Goldman Sachs. Your line is now live. Thanks for taking the question. Just going back to the Stellara biosimilar version and the acceleration of the trajectory that we're gonna see over the course of the year, Are you able to provide any quantitative framing on your views as it relates to the extent to which you think this, erosion gets smoothed out by the transition to other brands like Trampfire and other products? Thank you.

51m 23s

Well, good morning. Thanks so much for the question. It it's Jennifer.

51m 25s

So, what we saw with Stellara in the first quarter was definitely in line with our expectations. For the product for the year, and we continue to guide to the HUMIRA two year erosion curve once there were multiple biosimilars.

51m 41s

As, as really the best model there and make sure also including the additional impact of Part d redesign. If I could you know, one additional point around, Stellara, if we take a look at the business overall, it was highlighted that we had 4.2% growth across Innovative Medicine That included a negative eight ten basis point impact from Stellara. If you exclude that, from our business, the remaining business, the bulk 90% of our business was actually growing at over 12%, really demonstrating the strength of our overall business and with 11 key brands that were growing double digits. So yes, we've got the Stellara LOE, but the strength of the business is really coming through across all of our growth drivers.

52m 30s

Yes. And I would add to that. It is it is remarkable than in a year in which we are facing the headwind of the STELARA biosimilars partly redesign, we are able to grow even in the first quarter. And that we are able to do it, like any other company, to my knowledge, in the healthcare industry has done it. It's a testament to the strength of our business. The diversification of our growth platforms, And it gives me a strong belief that we are going to continue to deliver throughout the year.

53m 9s

Joaquin and Jeff are just building on the focus on Stellara. Of course, the Stellara begins to sunset, Tremfya continues to rise. You've seen the recent approvals in inflammatory bowel disease. Where Tremfya now is available as the only 23 class medicine for sub q delivery in both induction and maintenance.

53m 32s

We have generated additional strong data going head to head against Elara in a rigorous double blind study. And showing the superiority across all mucosal endpoints. So that's really disease model modifying, healing, Then finally, would say you'll see later this year data in psoriatic arthritis where we've done a, rigorous study looking at preservation of joint avoiding the joint erosion that leads to long term disability, and what you'll see in those data when they're presented is a best in disease profile for TREMFYA in psoriatic arthritis. Really excited about the progress with, Tremfya, the world's first selective IL-twenty three inhibitor.

54m 17s

Thank you. Next question today is coming from Danielle Antalffy from UBS. Your line is now live.

54m 22s

Hey. Good morning, everyone. Thanks so much for taking the question. Thanks so much too for all the the color on tariffs and the ortho impact. That was super And, Jess, we're we're really gonna miss you, but congrats. And good luck in your in your next role. Just to a quick question on you know? And maybe this isn't really a question I don't know. But I I think it's still on the table, and that's do we or don't we go into a recession? And I'd I'd love some color, if as much as you can provide on on how you guys think about your business and, how recession proof it is or isn't, and what areas might be most at risk of underperforming. Relative to where we are today in a in a recession. Thanks so much.

55m 8s

Hey, Danielle. Good to hear from you. Yeah. It's a good question. I think when, you know, we think about our business, the one thing we look to is certainly jobs reports in The US. And as of the most recent reports, it seemed to be pretty healthy. Well, the reason we look that is because it's a precursor as to who may have benefits and coverage. For, prescription medications as well as procedures. Inclusive of elective procedures. We have seen in times past when there's been a little bit of recession that some of those elective procedures, maybe get delayed, but they they don't get abandoned And I'm thinking primarily within orthopedics. You know, health care overall has proven to be, while nothing is immune to a recession, it's been a little bit more recession proof than most other industries. And so we'll continue to monitor that, but right now, we feel good about the the standards of care that we're elevating on both the innovative medicine and med tech side of the house.

56m 5s

Overall, demand remains solid and we feel good about the the rest of the year regarding procedures and use of pharmaceuticals. Don't know any comments on that team?

56m 18s

Sure. Further to Joe's point, Danielle, you know, the category such as advanced IOLs is a good precursor to really assessing the health of the economy.

56m 28s

And so far, we haven't seen any impact on the performance of our IOL portfolio. In fact, we've seen the opposite. When you look at the performance of our IOL business on the back of the launch of both Tecnus ODYSSEY here in The U. S. And PURE C globally. We're seeing benchmark performances and frankly, a turnaround of performance here in The U. S, would truly differentiate the innovation. And so, so far, no major headwinds. Thank you. Let question today is coming from Terence Flynn from Morgan Stanley. Your line is now live.

57m 4s

Hi, good morning. Congrats on the quarter, and thanks for taking the question. Joe, we heard your comments this morning on the Section two thirty two potential pharma tariffs being focused more towards generics API versus the complex branded biologics. So just wondering if that's based on your impression of the most likely outcome here or that's more just your speculation or hope for the outcome? Thank you.

57m 29s

Let me take that question, Terence, myself.

57m 32s

So we are analyzing Section two thirty two. It was already announced previously, so it's something that we consider normal that is going to happen. And overall, adding to my comments on tariffs before, I think it's also important that companies in healthcare partner with administration to look to mitigate some of the vulnerabilities that exist today in our healthcare supply chain so as to avoid any continuity of supply effects. So it's important for us to partner with the administration and with the government, and we plan to do it in this process to make sure that we have enough manufacturing capacity here in The U. S. To be able to address multiple scenarios.

58m 19s

And, Terrence, just to be clear, though, we wanna be deferential to the administration and their process. That is speculative just looking at the pharmaceutical landscape and where, you know, national security interest may reside. And what products there, that those, are delivered from. So that that was really kind of our take on it, but we are, working and engaging with the administration and being deferential to their process. [indiscernible] Next question today is coming from Joanne Wuensch from Citibank. Your line is now live.

58m 53s

Good morning, and thank you for taking the question and providing all of this information. Very helpful. I do wanna sort of just pause for a second on the orthopedic sales. And try to unpack how much of that is you know, which variable is there a way to quantify it, and how do we think about the recovery and the back half of the year and then into next year? Thank you.

59m 14s

Joanne, thank you for the question. As we mentioned, we've tripped to provide as much transparency as possible to the significant impact of one timers in the quarter, which, to your point, have disproportionately impacted the ortho business to the tune of roughly four eighty basis points. There are three key drivers to that Number one, the lapping of prior year change in walking implants revenue recognition fewer selling days and finally, revenue disruption from the recent Ortho transformation, which we announced in 2023. So when you actually look at our operational growth, when accounting for those, it would be closer to 2%. Now at the same time, will say, Joanne, we are not satisfied. Our underlying performance was by competitive pressures primarily in Spine and Sports, which is partially offset by strong NPIs and commercial execution in categories like Trauma, Shoulder and foot and ankle. What gives us confidence in continued acceleration to the back half of the year is the incredible impact of truly differentiated innovation across our Ortho portfolio. In fact, in 2024, we had eighteen five ten approvals here in The U. S, and 45 outside of The U. S. Across our portfolio. And what gives us is this combination of having best in class implants with truly differentiated enabled technology such as Vellus.

1h 34s

In our hips portfolio, we believe we're going to see continued performance on the back of our focus on interior approach, both with Actis Velis and KINCISE two point zero. In knees, we have seen a slowdown in revisions where I think you know we are historically number one. But feel very confident about continued momentum in primary with the combination of ATTUNE and VELYS, which is now available in 30 markets We have 110,000 procedures. And as you probably know, we're now launching the Veloci U knee knee in the coming quarters. In trauma, this was a standout quarter for us. Close to 7.3% operational growth when you account for the one timers, and this was driven by a tremendous uptake of our Volt plating system, the feedback we've got from surgeons, especially for our small frat our mini frag and our distal radius has been exceptional. I think you also know that spine has been a bit of a laggard for us in the ortho portfolio. We are now effectively launching the TriAlta Spine system, which is a thoracolumbar system. Coupled with VeloSpine, also launching in the couple in the coming quarters. And so not the best start, but strong confidence in improved performance for the remainder of the year in Ortho.

1h 1m 44s

Thank you. Next question today is coming from Vamil Divan from Guggenheim Partners. Your line is now live.

1h 1m 49s

Great. Thanks for taking the question and for all the information.

1h 1m 53s

I just wanted to maybe focus on that Slide 29, Joe, that you talked about. I don't know if this is for you, Joe, or for for Jennifer. Appreciate you sharing your perspectives on those products and how they differ expectations differ from consensus. There's three products that are not on there anymore that were there. At the end of twenty twenty three, and that's [indiscernible] [indiscernible] And I don't think the consensus expectations have changed for those. Very much since then. So maybe you can just talk about you know, what has changed there, why those aren't listed. Has there anything changed from your internal perspectives or or, again, externally that just had those come off of that list. Thank you.

1h 2m 30s

Hi, Vamil. This is Jess. Yes. You're absolutely correct. The multiple myeloma portfolio was on the slide during the EBR in 2023, and they are not on the slide today. Not saying that there's not still a disconnect, but it's just not to the extent of the other products on the list. At that time, we had estimated if you did the math on the slide, it would have been about $4,000,000,000 that would have been added to 2027. Around 2,000,000,000 was added, so those estimates did go up at that time. Again, not that there's not still a discount It's just not to the extent of the others on the slide because those estimates were increased.

1h 3m 12s

Yeah. So just to be super clear on that one, Vamil, we are still extremely bullish based on the clinical progression, r and d, as well as the performance that we're seeing in the marketplace. I mean, look at CarVictee, I think doubled sales year on year. So it's just a matter that, you guys took your numbers up and so agree. I guess this maybe the best way to say that.

1h 3m 36s

And maybe just to add in a little bit more on Carvicti. So, yeah, over a % operational growth in the first and we continue to make very strong share gains in that second line plus, indication. We continue add sites. We continue to add countries. And capacity expansion globally. And so we have very firm conviction in Carvick D as a $5,000,000,000 plus asset. And really are rolling that out, globally very effectively at this point in time. So we don't see capacity as a constraint going forward based on the strength of the efforts that have taken place in you know, we're full speed ahead for Carvicti going forward.

1h 4m 18s

And with the TechIntel, John here, you know, we're really just getting started. You've probably seen some of the recent data where we've even combined those two molecules to achieve really unprecedented levels of complete responses. At the, hematology meetings last year, we also showed combining either Tekratau with DARZALEX and demonstrating really impressive % minimal residual disease negative in earlier lines of therapy and the opportunity, therefore, to really start bringing these first in class bispecific T cell reader molecules into earlier lines, even frontline in combination with our DARZALEX. So really, enormous opportunity lies ahead of us with TechIntel.

1h 5m 5s

And and a couple other things on TechIntel. So, we continue to expand. We've got very good penetration in the academic settings right now. And we continue to expand out into the community. We've got very strong new patient starts I know that the products have been plagued a little bit, because the product is so effective some less frequent dosing. As we move forward, we should be lapping that soon. And really, you'll see the strength of those new patient starts and the continued expansion into the community we're starting to show through. Combined then with what John talked about in terms of additional combinations and such, we got, very strong convictions and we remain convinced on the opportunities tech and talent.

1h 5m 49s

Thank Next question is coming from Matt Miksic from Barclays. Your line is now live.

1h 5m 54s

Great. Thanks so much for taking the question. Questions and appreciate all the color I had I had a clarification and and a question if I could. So the question first, You know, would be great if you could maybe flesh out the way that you know, the opportunities in Trampaya, you know, which is now kinda leaning into IBD and the emerging opportunities for icotrokinra in oral kind of you know, and you see them coming together, you know, this year, next year, year after, as as kind of a portfolio. [indiscernible] immuno. And then the clarification, if I could, just for Tim, sounded like when you were describing the the ortho impacts, the two something like 2%. But if you look at the hyponymic math, it's if I'm right, it looks like about 2% in The US.

1h 6m 48s

I just wanna make sure I understand. It sounded like your your view was that's that's shared. That's on us. You know, And and we're gonna remedy that with with innovations and new products this year. Maybe [indiscernible] put two spine of a point on it, but, like, that's not market growth. Like, two Like, you would say we're we're below market, and we should be doing better. Or do or do you think that you know, that's kinda where the market's at is in that, like, low single digit range for US citizen needs. Thanks so much. I'm apology, for the long long clarification, but be super helpful. Thanks.

1h 7m 25s

Matt, let me start with, your question on on on ortho. And, to be perfectly frank, while we have seen an improvement in our performance both in hips and knees through 2024, Q1 clearly wasn't our strongest quarter. And so we have seen competitive As you know, these are highly attractive categories within ortho. It's where primarily fight is. And frankly, we need to do better. And so we believe that our performance so far in quarter was slightly below market. These are attracting markets. We've seen a, you know, strong robust procedures across Ortho, and we expect that to continue, as I mentioned, with the addition of our portfolio of both implants as well as enabling technologies technology across hips and knees, we're confident that we will see an improvement through the remaining quarters. Thank you.

1h 8m 14s

Great. So let's switch over to TREMFYA and immunology. And Trumfya really had a great quarter in the first quarter with sales nearly a billion dollars. And over 20% operational growth. And this was really driven by market share gains in psoriasis and psoriatic arthritis, as well as what we're seeing as it relates to the launch in ulcerative colitis and also in Crohn's disease. So we are really encouraged by the launch in both of these IBD indications TREMFYA is now, if we start with with ulcerative colitis and how we're doing, and then I'll go to Crohn's disease, So in ulcerative colitis, TREMFYA is the fastest growing product. In the ulcerative colitis market. IL-23s are the fastest growing class, and Tremfya has already achieved nearly a 50% share of the IL-twenty three new patient starts in UC. So this is really based on the strength of the profile of the product and the strong differentiation that we have as a dual acting IL-twenty three both impacting both IL-twenty three as well as CD64. The robust data that we have as it relates to efficacy and remission And then as we get into Crohn's disease and then later in ulcerative colitis, as well, what we see is unrivaled simplicity with the opportunity for subcu and induction, as well as maintenance dosing.

1h 9m 37s

When we take a look at market research data and intent to prescribe, the data comes through really strong that gastroenterologists really prefer Tremfya over the IL IL-twenty three competitors, based on those aspects that I just discussed. So efficacy, sustained remission and mucosal healing right now for UC On Crohn's, there is very significant enthusiasm around our launch there, and it's really quickly getting, traction. In the first few weeks since approval in Crohn's disease, patient initiation volumes are outpacing. The other -twenty three launches in the market. And the polling data, the you know, our recent market research, eighty two percent of gastroenterologists consider TREMFYA's induction dosing and flexibility to be a very differentiation in their treatment decisions. They're seeing the efficacy profile to be quite compelling compared to the other therapies that are in the market. So we believe that in IBD, both in ulcerative colitis and Crohn's, we're off to a strong start. And as a reminder, tracking back to Stellara, Stellara, seventy five percent of sales were in IBD indications. We see no reason why Tremfya wouldn't be the same or even better based on what we're seeing with the strength and competitiveness of the profile.

1h 11m 1s

And maybe just a comment on iCotrokinra since you, asked about that. The most proximal opportunity there is our psoriasis campaign where we will have altogether five phase three studies Data for that this year, we expect to submit this year. For psoriasis. So excited to be able to offer patients more choice [indiscernible] a market like psoriasis, which, you know, is should be well it is a place where some of the biologics first, got their start. More than half of patients are who are eligible for advanced therapy or still not on advanced therapy. And for many of these patients, it's really, an aversion to the injection and going the biologics route. So to be able to offer patients the choice of a once a day pill to provide a solution for their disease, which has efficacy in the same ballpark as the biologics and with that well proven safety profile of the IL twenty three class is really exciting for us.

1h 12m 8s

Yeah.

1h 12m 9s

We we really believe that icotrokinra is a big market expansion opportunity, to get in those earlier lines of therapy and to bring patients into therapies that have that strong biologic like efficacy. We think that there is a lot of room, for both icotrokinra and TREM5 in the market, based on different patient needs, different physician needs as well. And so we think both of these are very important growth drivers for us going forward.

1h 12m 38s

Thank you, Matt. Kevin, we have time for one last question.

1h 12m 41s

Thank you. Our final question today is coming from Tim Anderson from Bank of America. Your line is now live. Going back to tariffs, a big concern by investors is how that might ultimately wrap in transfer pricing structures and every company I know is usually hesitant to talk about that. I'm wondering what J and J can offer up on that front. That could include things like major products where you have transfer price structures in place.

1h 13m 12s

Well as which geographies you have those in place? As well.

1h 13m 16s

Yeah. I appreciate the question, Tim. Just not something that, for competitive reasons, we're going to comment on.

1h 13m 24s

Yeah. I would reiterate what I what I said before. With our $55,000,000,000 investment plan at the completion of that plan. Which we spoke about four years, all our advanced medicines that are used in The U. S. Will be manufactured here in The U. S. So that's our plan and that's why we believe it's important to provide discontinuity. As I said before, after 02/2017, president Trump's, tax reform, the level of investments in The U. S. Have increased and we plan to continue to increase it given the current regime or improvements that may come into the future.

1h 14m 6s

Thank you, Tim. And thanks everyone for your questions and your continued interest in our company. We apologize to those that we couldn't get to because of time, but don't hesitate to reach out to the Investor Relations team with any remaining questions that you may have. As many of you have seen, Darren Snellgrove will be transitioning into the Investor Relations role starting May 1 as I transition into the Innovative Medicines CFO role.

1h 14m 31s

The last three and a half years have been an absolute pleasure getting to engage with you all. I will now turn the call over to Joaquin for some brief closing remarks.

1h 14m 40s

Thank you, Jess, and thank you, everyone, for joining the call today. As you heard, 2025, it's going to be a catalyst year for Johnson and Johnson. And with our Q1 results, we are off to a great start. This start reflects the power of Johnson and Johnson's uniquely diversified business model, and further strengthens our confidence in our 2025 guidance and beyond. Thank you very much.

1h 15m 15s

Thank you. This concludes today's Jonathan and Johnson First Quarter twenty twenty five Earnings Conference Call. You may now disconnect.

Key Insights

Johnson & Johnson reported strong Q1 2025 results, with 4.2% operational sales growth and $21.9B in worldwide sales, driven by double-digit growth in key brands across both Innovative Medicine and MedTech, despite headwinds from Stellara biosimilar competition and Part D redesign.
The company raised full-year 2025 operational sales guidance by $700M to a range of 3.3%–4.3% growth (midpoint $92B), reflecting the addition of CAPLYTA from the Intracellular acquisition; adjusted EPS guidance is maintained at $10.50–$10.70 (6.2% growth at midpoint).
Innovative Medicine saw robust performance, with DARZALEX sales up 22.5%, Tremfya up 20.1% (driven by new IBD indications), and Carvykti and Tecvayli both showing strong launches; MedTech grew 4.1% operationally, with notable contributions from Abiomed, Shockwave, and new product launches, though orthopedics was impacted by one-time events.
The pipeline advanced with key regulatory milestones: Tremfya approved for Crohn’s disease, Ribrevant plus Lascluse showing >1 year OS benefit in lung cancer, and CAPLYTA expected to be approved for adjunctive major depressive disorder later this year; icotrokinra (oral IL-23 inhibitor) showed strong Phase 3 results in psoriasis and is expected to be filed in 2025.
J&J announced a $55B US investment over four years in manufacturing, R&D, and technology, increased its dividend for the 63rd consecutive year, and remains confident in long-term growth, projecting several pipeline assets (Tremfya, Ribrevant+Lascluse, icotrokinra) to exceed current street estimates for peak sales beyond 2028.

Recent Transcripts

Johnson & Johnson delivered 4.2% operational sales growth in Q1 2025 and raised full-year outlook.

Johnson & Johnson delivered strong 2024 results, exceeding sales targets and guiding for robust 2025 growth.

Income Statement

Revenue

	2021	2022	2023	2023	2024
Revenue	$83B	$79B	$85B	$85B	$89B
Cost of Revenue	$28B	$23B	$27B	$27B	$27B
Gross Profit	$54B	$55B	$59B	$59B	$61B
Gross Profit %	66%	70%	69%	69%	69%
R&D Expenses	$12B	$14B	$15B	$15B	$17B

2021

2022

2023

2024

Revenue

$83B

$79B

$85B

$89B

Cost of Revenue

$28B

$23B

$27B

Gross Profit

$54B

$55B

$59B

$61B

Gross Profit %

66%

70%

69%

R&D Expenses

$12B

$14B

$15B

$17B

Cash Flow

Net Income

	2021	2022	2023	2023	2024
Net Income	$15B	$21B	$13B	$13B	$14B
Dep. & Amort.	$7.2B	$7.4B	$7.5B	$7.5B	$7.3B
Def. Tax	-$1.1B	-$2.1B	-$4.2B	-$4.2B	-$2.2B
Stock Comp.	$1B	$1.1B	$1.2B	$1.2B	$1.2B
Chg. in WC	$2.7B	-$4.2B	$2.5B	$2.5B	$1.8B

2021

2022

2023

2024

Net Income

$15B

$21B

$13B

$14B

Dep. & Amort.

$7.2B

$7.4B

$7.5B

$7.3B

Def. Tax

-$1.1B

-$2.1B

-$4.2B

-$2.2B

Stock Comp.

$1B

$1.1B

$1.2B

Chg. in WC

$2.7B

-$4.2B

$2.5B

$1.8B

Balance Sheet

Cash

	2021	2022	2023	2023	2024
Cash	$14B	$14B	$22B	$22B	$24B
ST Investments	$11B	$17B	$1.1B	$1.1B	$417M
Cash & ST Inv.	$25B	$32B	$23B	$23B	$25B
Receivables	$14B	$15B	$15B	$15B	$19B
Inventory	$9.3B	$10B	$11B	$11B	$12B

2021

2022

2023

2024

Cash

$14B

$22B

$24B

ST Investments

$11B

$17B

$1.1B

$417M

Cash & ST Inv.

$25B

$32B

$23B

$25B

Receivables

$14B

$15B

$19B

Inventory

$9.3B

$10B

$11B

$12B

Go Deeper

Financial information provided by Financial Modeling Prep. Options data provided by Unusual Whales. Live transcripts provided by Quartr. Reported revenue and EPS data from Earnings powered by FinChat.io. All data is provided for informational purposes only, and is not intended for trading purposes or financial, investment, tax, legal, accounting or other advice. · See all tickers.

Overview
Latest News
Earnings
Income Statement
Cash Flow
Balance Sheet
Related

Earnings

Report Date

Apr 15, 2025

Reported Revenue

21.9B

Beat +1.55%

Avg 1d Change

1.91%

Report Period

Q1 2025

Reported EPS

2.8

Beat +7.36%

Implied Move 1d

2.29%

Transcript

6m 27s

7m 52s

9m 45s

11m 33s

13m 23s

14m 56s

15m 53s

Thank you, Joaquin.

15m 55s

17m 35s

19m 14s

20m 37s

21m 12s

22m 22s

22m 40s

24m 18s

26m 8s

27m 20s

29m 8s

30m 40s

30m 54s

32m 30s

34m 7s

And I will now turn the call over to Joe.

34m 10s

35m 22s

37m

37m 50s

39m 24s

40m 45s

42m 22s

43m 48s

44m 28s

44m 52s

45m 40s

46m 54s

47m 22s

Thank you, Joe, and thank you, Larry, for the question.

47m 26s

48m 40s

49m 10s

49m 27s

And just the outlook going forward as we consider mix, tariffs, etcetera, on on the gross margin line? Thank you.

49m 33s

50m 47s

Year over year. And that one, was probably a little bit of a miss, so we probably could 've done a better job explaining it.

50m 57s

51m 23s

Well, good morning. Thanks so much for the question. It it's Jennifer.

51m 25s

51m 41s

52m 30s

53m 9s

53m 32s

54m 17s

Thank you. Next question today is coming from Danielle Antalffy from UBS. Your line is now live.

54m 22s

55m 8s

56m 5s

Overall, demand remains solid and we feel good about the the rest of the year regarding procedures and use of pharmaceuticals. Don't know any comments on that team?

56m 18s

Sure. Further to Joe's point, Danielle, you know, the category such as advanced IOLs is a good precursor to really assessing the health of the economy.

56m 28s

57m 4s

57m 29s

Let me take that question, Terence, myself.

57m 32s

58m 19s

58m 53s

59m 14s

1h 34s

1h 1m 44s

Thank you. Next question today is coming from Vamil Divan from Guggenheim Partners. Your line is now live.

1h 1m 49s

Great. Thanks for taking the question and for all the information.

1h 1m 53s

1h 2m 30s

1h 3m 12s

1h 3m 36s

1h 4m 18s

1h 5m 5s

1h 5m 49s

Thank Next question is coming from Matt Miksic from Barclays. Your line is now live.

1h 5m 54s

1h 6m 48s

1h 7m 25s

1h 8m 14s

1h 9m 37s

1h 11m 1s

1h 12m 8s

Yeah.

1h 12m 9s

1h 12m 38s

Thank you, Matt. Kevin, we have time for one last question.

1h 12m 41s

1h 13m 12s

Well as which geographies you have those in place? As well.

1h 13m 16s

Yeah. I appreciate the question, Tim. Just not something that, for competitive reasons, we're going to comment on.

1h 13m 24s

1h 14m 6s

1h 14m 31s

The last three and a half years have been an absolute pleasure getting to engage with you all. I will now turn the call over to Joaquin for some brief closing remarks.

1h 14m 40s

1h 15m 15s

Thank you. This concludes today's Jonathan and Johnson First Quarter twenty twenty five Earnings Conference Call. You may now disconnect.

Key Insights

Johnson & Johnson reported strong Q1 2025 results, with 4.2% operational sales growth and $21.9B in worldwide sales, driven by double-digit growth in key brands across both Innovative Medicine and MedTech, despite headwinds from Stellara biosimilar competition and Part D redesign.
The company raised full-year 2025 operational sales guidance by $700M to a range of 3.3%–4.3% growth (midpoint $92B), reflecting the addition of CAPLYTA from the Intracellular acquisition; adjusted EPS guidance is maintained at $10.50–$10.70 (6.2% growth at midpoint).
Innovative Medicine saw robust performance, with DARZALEX sales up 22.5%, Tremfya up 20.1% (driven by new IBD indications), and Carvykti and Tecvayli both showing strong launches; MedTech grew 4.1% operationally, with notable contributions from Abiomed, Shockwave, and new product launches, though orthopedics was impacted by one-time events.
The pipeline advanced with key regulatory milestones: Tremfya approved for Crohn’s disease, Ribrevant plus Lascluse showing >1 year OS benefit in lung cancer, and CAPLYTA expected to be approved for adjunctive major depressive disorder later this year; icotrokinra (oral IL-23 inhibitor) showed strong Phase 3 results in psoriasis and is expected to be filed in 2025.
J&J announced a $55B US investment over four years in manufacturing, R&D, and technology, increased its dividend for the 63rd consecutive year, and remains confident in long-term growth, projecting several pipeline assets (Tremfya, Ribrevant+Lascluse, icotrokinra) to exceed current street estimates for peak sales beyond 2028.

Johnson & Johnson Price & Performance (JNJ)

Stock Performance

Open

Market Cap

Year High

High

P/E Ratio

Year Low

Low

Dividend Yield

Volume

Latest News

What's Happening

Peers

Earnings

Report Date

Reported Revenue

Avg 1d Change

Report Period

Reported EPS

Implied Move 1d

Transcript

Key Insights

Recent Transcripts

Income Statement

Cash Flow

Balance Sheet

Go Deeper

Related

Go Deeper

Latest News

Recent Transcripts

Earnings

Report Date

Reported Revenue

Avg 1d Change

Report Period

Reported EPS

Implied Move 1d

Transcript

Key Insights